Trials / Active Not Recruiting
Active Not RecruitingNCT03692143
Comparation of Treatment Strategies for OVF: Teriparatide Injection and PVP
Effect and Cost Comparation of Different Treatment Strategies for Osteoporotic Vertebral Fractures (OVF): Teriparatide Injection and Percutaneous Vertebroplasty (PVP)
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 90 (estimated)
- Sponsor
- Nanfang Hospital, Southern Medical University · Academic / Other
- Sex
- Female
- Age
- 49 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This study aimed to compare teriparatide treatments and PVPs, focusing on its effects on life qualities and effect/coast ratio and evaluate which method is better for patients.
Detailed description
Osteoporosis and osteoporotic vertebral fracture (OVF)s are the common diseases that affect the qualities of senior people. The general treatments for OVFs including percutaneous vertebroplasty (PVP) operation and conservative treatments with pain killers. But with the widely used methods, the life quality of patients were still not satisfied. Teriparatide has been proven to increase bone qualities in patients with severe osteoporosis and reduced the fracture possibilities. The investigators' previous clinical observation found teriparatide could be applied to treat fresh OVFs. 90 participants who diagnosed fresh OVFS were included in the trial. After they received each of three kinds of interventions mentioned in this study, The investigators followed up all these cases. Once 30 cases goal reaches in a certain group, the data collection in that special will stop automatically. The quality of life, pain score and BMDs will be evaluated in certain time during the trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Teriparatide | subcutaneous injection of teriparatide(20 mg) once daily |
| PROCEDURE | PVP | With local anesthesia, bone cement was injected in to fractured body in a needle that penetrated transpedically and percutaneously |
| DRUG | Alendronate | Alendronate Sodium, oral, 70mg, once a week |
Timeline
- Start date
- 2017-01-01
- Primary completion
- 2025-03-01
- Completion
- 2030-12-01
- First posted
- 2018-10-02
- Last updated
- 2018-10-02
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03692143. Inclusion in this directory is not an endorsement.